Abstract
Cell adhesion molecules regulate synapse formation and maintenance via transsynaptic contact stabilization involving both extracellular interactions and intracellular postsynaptic scaffold assembly. The cell adhesion molecule neurofascin is localized at the axon initial segment of granular cells in rat dentate gyrus, which is mainly targeted by chandelier cells. Lentiviral shRNA-mediated knockdown of neurofascin in adult rat brain indicates that neurofascin regulates the number and size of postsynaptic gephyrin scaffolds, the number of GABAA receptor clusters as well as presynaptic glutamate decarboxylase-positive terminals at the axon initial segment. By contrast, overexpression of neurofascin in hippocampal neurons increases gephyrin cluster size presumably via stimulation of fibroblast growth factor receptor 1 signaling pathways.
Keywords: Axon, Brain, GABA Receptors, Gene Silencing, Synapses, FGFR1, Axon Initial Segment, Gephyrin, Neurofascin
Introduction
Signal transduction in the nervous system relies on an elaborate balance between excitatory and inhibitory synaptic transmission. Formation and stabilization of both types of synapses involve the recruitment of cell surface molecules and intracellular scaffold components to postsynaptic sites (1). Cell adhesion molecules are thought to stabilize synaptic contacts as exemplified by postsynaptic neuroligin interactions with presynaptic neurexins (2). For example, neuroligin 2 is involved in the stabilization of dendritic (3) and perisomatic inhibitory synapses (4). However, little is known about the stabilization of axo-axonic GABAergic synapses targeting the axon initial segment (AIS).4 The AIS of cortical and hippocampal neurons is a specialized region that receives input mainly from axo-axonic GABAergic interneurons (5). Chandelier cells represent the prominent class of interneurons providing presynaptic terminals to the AIS (6). Chandelier cells are parvalbumin-positive interneurons that extend rows of presynaptic boutons for axo-axonic innervation along the AIS. Chandelier terminals are strategically located at the site of action potential initiation and are therefore suspected to regulate neuronal signal propagation, the precise mechanism being under dispute (7). Interestingly, reduced GABAergic innervation at the AIS of cortical layer 2/3 pyramidal neurons appears to be specific to the disease process of schizophrenia (8).
The AIS represents a special compartment in neurons that is characterized by the presence of specific proteins (9) including ankyrin G, βIV spectrin, β1 subunits of sodium channels, and neuronal cell adhesion molecules neurofascin and NrCAM (10–12). Neurofascin is expressed in different major isoforms generated by alternative splicing, e.g. NF155, NF166, and NF186 (13). Although NF155 is found in glia, the neuronal NF186 isoform is tethered to the ankyrin-based cytoskeleton at AIS where it may serve as a organizer of the perineuronal net (14) and contributes to sodium channel clustering at the nodes of Ranvier (15, 16). By contrast, NF166 is implicated in the induction of neurite outgrowth via FGFR1 signaling (17) and may be involved in the induction of gephyrin clusters in immature hippocampal neurons devoid of differentiated AIS (18). However, the role of neurofascin in the maintenance of inhibitory input in the adult brain is still unclear because of early mortality of neurofascin knock-out mice (16). Here, we apply in vivo studies in the adult brain in combination with in vitro systems to study the function of neurofascin in the organization of gephyrin clusters and the stabilization of presynaptic axo-axonic input at the AIS.
EXPERIMENTAL PROCEDURES
Lentiviral Vector Construction and Lentiviral Production
A CamKII/EGFP/woodchuck hepatitis virus posttranscriptional regulatory element-expression cassette from L22 FCK-1.3 (Pavel Osten) was introduced into pLenti6/BLOCK-iTTM-DEST (Invitrogen) to yield pLenti/CEW. Subsequently, control (shCTR) and neurofascin-specific (shNF252/1504) shRNA sequences were integrated via Gateway® recombination (VirapowerTM Lentiviral Expression System; Invitrogen), and lentiviral particles were produced according to the manufacturer's protocols (viral titers approximately 5 × 107 transducing units/ml).
Animals, Stereotactic Surgery, Transcardial Perfusion
Adult female Sprague-Dawley rats (250 g at time point of surgery; Charles River Laboratories) were kept in compliance with the European Union recommendations for the care and use of laboratory animals and as approved by the responsible regional council. For stereotactic injection of lentiviral suspension, animals were deeply anesthetized by injection of ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively). Bilateral injections of 4 μl of lentiviral suspensions into the dorsal dentate gyrus (AP: −2.9 mm, ML: ± 2.5 mm, DV: −4.3 mm; all coordinates relative to Bregma) were conducted using a Lab StandardTM Stereotaxic Instrument (Stoelting Co., Wood Dale, IL) connected to a 701 RN Hamilton syringe (10 μl, 30 gauge, pst 4; CS-Chromatographie Service, Langerwehe, Germany). Injection speed was set to 0.2 μl/min. For fixation of brain tissue, animals were deeply anesthetized as described above and perfused transcardially with 200 ml of 1 × PBS followed by 500 ml of 4% paraformaldehyde/PBS.
Cell Culture and Transfection
Culture and transient transfection of HeLa cells and primary neurons were performed as described previously (18, 19). Primary hippocampal neurons were cultured at high density (2 × 105 cells/cm2). Transfection was performed at 10 days in vitro (DIV), and cultures were processed for imaging at 17 DIV. Plasmids used were: pEGFP-C2/gephyrin, pRK5myc/collybistin II (CB2SH3-), pcDNA3.1myc-his/FGFR1 and pEGFP-N1/FGFR1-DN (17), expression vectors for chick neurofascin-166, −166ED, −166CD, and −186 (18), pCMV/NCAM (full-length NCAM180 cDNA cloned into pEGFP-N1 (Clontech) via XhoI and NotI restriction sites, pCMV/GABAAR-α2 and pCMV/GABAAR-β3 (full-length subunits cloned into pEGFP-N1 via SacII-NotI restriction sites), pEGFP-N1/GABAAR-γ2, pcDNA3.1-L1 (kindly provided by Vance Lemmon). Equal amounts of plasmid DNA were transfected in all cases. Inhibitors were dissolved in dimethyl sulfoxide and added to the cell culture medium at the start of transfection to a final concentration of 20 μm for FGFR1 inhibitor SU5402, 10 μm for MEK inhibitor U0126, and 10 μm for PI3K inhibitor LY294002.
Immunohistochemistry
For immunohistochemistry the following primary antibodies were used: anti-gephyrin (mAb7a, 1:100; Synaptic Systems, Göttingen, Germany), mAb anti-voltage-gated sodium channel (VGSC) (1:100; Sigma-Aldrich), polyclonal antibodies anti-GAD65 (1:1000; Millipore), anti-GAT1 (1:500; Millipore), anti-neurofascin (17), anti-VGSC (1:100; Sigma-Aldrich), and anti-NCAM (1:100, kind gift from V. Berezin and E. Bock). Perfusion-fixed brains were washed in PBS and cut into 100-μm slices using a vibrating microtome (Vibroslice 752 M; Cambden Instruments, Loughborough, UK). After permeabilization (0.6% Triton X-100), slices were blocked by 1 × BMB blocking reagent/PBS (Roche Applied Science) for 1 h at room temperature. Further processing of brain slices and immunocytochemical staining were performed as described (18, 19). Specimens were mounted on microscopic slides using Dako Fluorescent Mounting medium (Dako GmbH, Hamburg, Germany).
Image Acquisition and Statistical Analysis
Confocal fluorescence images were acquired at 23 °C using a Zeiss LSM510 Meta confocal microscope equipped with a 63× Plan-Apochromat oil immersion objective (NA 1.4; Carl Zeiss AG, Oberkochen, Germany). Z-stack images of hippocampal slices were recorded, processed and analyzed as detailed in the supplemental text (Imaris software package, Bitplane AG, Zurich, Switzerland). HeLa cells were fixed and analyzed 24 h after transient transfection. For quantitative analysis of gephyrin cluster size, images of 20–40 cells were taken using the Zeiss LSM510 Meta confocal microscope equipped with a 63× Plan-Apochromat oil immersion objective. The images were analyzed using Imaris software package. The areas of individual gephyrin clusters were determined and used to calculate the mean size of individual gephyrin clusters. At least three independent transfections or animals were used for each experiment shown.
RNA Preparation and RT-PCR Analysis
Total RNA from rat brain tissue (Sprague-Dawley) was prepared using RNA-STAT60 reagent according to the manufacturer's guidelines (AMS Biotechnology, Milton, UK). Total RNA from staged hippocampal neurons was isolated using the RNAqueous®-4PCR Kit (Ambion, Austin, TX). cDNA synthesis was performed with the High Capacity RNA-to-cDNA Kit (Applied Biosystems). SYBR Green quantitative RT-PCR to amplify neurofascin-specific sequences was carried out on the 7500 Fast Real-Time PCR System (Applied Biosystems) using the following primer sets: NF186-F (TGGAAGCACAATTTCAGGCC) and NF186-R (CTGATGCCCTCGTTGTCCCG), NF166-F (GTACCTACCACCGTCGCCA) and NF166-R (TGGTGTAAGCGGTTTCGTGA), GAPDH-F (TGCACCACCAACTGCTTAGC) and GAPDH-R (GGCATGGACTGTGGTCATGAG).
RESULTS
Neurofascin Is Expressed on Axon Initial Segments of Granular Cells in the Dentate Gyrus
Hippocampal slices from rat brain were immunostained for neurofascin, VGSC as a marker for the AIS, as well as GABA transporter 1 (GAT-1), GAD65, and gephyrin as presynaptic and postsynaptic markers of GABAergic synapses. Different neurofascin isoforms are expressed both in neurons and glial cells. For unambiguous allocation of neuronal neurofascin, single granular cells were labeled via lentiviral expression of EGFP driven by the Ca2+/calmodulin-dependent protein kinase II (CamKII) promoter (Fig. 1A; for details see the supplemental figure). Rendered images of EGFP-labeled granular cells (Fig. 1A′) were used to identify VGSC and neurofascin signals as shown in Fig. 1A″ and 1A‴. VGSC colocalizes with neurofascin, indicating that neurofascin is localized at the AIS of granular neurons in the dentate gyrus as previously observed in dissociated hippocampal neurons (18). Pan-VGSC antibodies were used recognizing all known vertebrate VGSCs. Previous reports have documented that axo-axonic interneurons target the AIS of hippocampal pyramidal and granular cells (20). At the AIS, presynaptic terminals of axo-axonic, parvalbumin-positive chandelier neurons can be stained for GAT-1 (6). As shown in Fig. 1, B–D, GAT-1-, GAD65-, and gephyrin-positive punctae were found at the VGSC-positive AIS in accordance with previous findings (21). Likewise, 11–12 puncta for GAD65, GAT-1, and gephyrin per AIS were identified (Fig. 1F), suggesting that components of synapses formed by chandelier cells were stained. As shown in Fig. 1, E–E‴, all gephyrin-positive clusters were opposed to a presynaptic GAD65 signal on the granule cell AIS. Hence, neurofascin is located on the AIS of granular cells in the dentate gyrus targeted by GABAergic presynaptic terminals.
Neurofascin Is Required for the Stabilization of GABAergic Synapses
To analyze a possible role of neurofascin in synapse stabilization in the adult dentate gyrus, neurofascin expression was inhibited by lentiviral shRNA expression after stereotactic injection in rat brain. Specificity, the efficacy and absence of off-target effects have been assessed in a previous report (18). Lentiviral vectors for the expression of an ineffective control shRNA (shCTR), neurofascin-specific shRNAs (shNF252 and shNF1504) together with CamKII promoter-driven EGFP were injected into the rat dentate gyrus. After 14 days, hippocampal slices were stained for the presynaptic marker GAD65 and postsynaptic gephyrin as well as VGSC as an AIS marker. Infected granular cells were identified via EGFP expression (Fig. 1). The number of GAD65, gephyrin, or GABAA receptor subunit β2/3 punctae did not significantly differ on the AIS of shCTR-infected and uninfected neurons, indicating that lentiviral infection alone did not interfere with synapse stability (Fig. 2, M, Q, and U). By contrast, infected neurons expressing shNF252 displayed <50% of GAD65, gephyrin, or GABAAR subunit β2/3 punctae at the AIS compared with controls (Fig. 2, J, N, and R). The effects observed are unlikely to be due to off-target effects, because an independent neurofascin-specific shRNA vector (shNF1504) was equally effective (Fig. 2V). Crucially, inspection of GAD65, gephyrin, or GABAAR subunit β2/3 clusters on somata or dendrites did not reveal significant differences in puncta number (Fig. 2, K, L, O, P, S, and T). Hence, the observed reductions for GABAergic markers were specific for the AIS, reflecting the specificity of neurofascin expression in this structure.
We also examined the mean gephyrin cluster volume and the total gephyrin cluster volume per AIS after neurofascin knockdown. As expected, the total cluster volume per AIS was significantly decreased, in accordance with the observed reduction in gephyrin cluster number (Fig. 2X). Interestingly, knockdown of neurofascin also decreased the mean gephyrin cluster volume (Fig. 2W). Thus, as well as controlling gephyrin cluster number, neurofascin may also be involved in the control of gephyrin cluster size.
VGSC staining was used to identify the AIS of infected and uninfected granular cells. Because neurofascin is thought to regulate the surface expression of sodium channels (22), we quantified immunohistological staining for VGSC after knockdown of neurofascin in vivo (Fig. 2Y). However, we did not observe any differences in VGSC staining between control and shNF252-infected neurons at the AIS. This finding is consistent with a recent report that neurofascin knockdown in hippocampal neurons does not interfere with VGSC or ankyrin G localization at the AIS (23). Consequently, lentiviral knockdown of neurofascin does not impair the expression of the AIS marker VGSC in vivo.
Neurofascin Overexpression Modulates Gephyrin Clustering in Hippocampal Neurons
Two functionally distinct neuronal neurofascin isoforms are found in brain, mainly differing in the expression of the fifth FNIII-like repeat which is absent in NF166 (NF−5.FNIII) and present in NF186 (NF+5.FNIII) (19, 24). Analysis of the expression of neurofascin in rat brain revealed (Fig. 3H) that NF−5.FNIII is expressed in a 7-fold and 37-fold excess over NF+5.FNIII at embryonic day 17 and postnatal day 3. By contrast, the ratio was reversed in the adult brain. Here, NF+5.FNIII was expressed in a 33-fold excess over NF−5.FNIII. This indicates that predominant NF+5.FNIII expression is a hallmark of mature neurons in vivo. Inspection of cultured hippocampal neurons revealed that the ratio of NF−5.FNIII to NF+5.FNIII continuously declined from 18.3 (5 DIV) to 0.7 (39 DIV) (Fig. 3G). Hence, cultured neurons differ from adult brain in the increased expression of NF−5.FNIII.
Next, the impact of neurofascin NF166 (NF−5.FNIII) was examined after overexpression in primary hippocampal neurons. Although the number of endogenous gephyrin clusters remained unaffected, NF166 decreased the average size of individual gephyrin clusters (Fig. 3, A and B). On the other hand, cotransfection of neurofascin NF166 and EGFP-gephyrin increased cluster size, indicating that endogenous and overexpressed gephyrin were regulated differently (Figs. 3C and 4, A and B). To address possible overexpression artifacts, we included further controls to analyze clustering of exogenous EGFP-gephyrin. Overexpression of the alternative neurofascin isoform NF186 was ineffective (Fig. 3C). Likewise, overexpression of neurofascin NF166 deletion mutants lacking either the intracellular or the extracellular domain (NF166-ED and NF-CD, respectively) did not increase gephyrin cluster size, indicating that full-length neurofascin is required for increasing gephyrin cluster size in primary neurons. Finally, EGFP-gephyrin colocalizes with endogenous γ2 subunits of GABAA receptors both in the presence and absence of neurofascin NF166 expression, indicating that EGFP-gephyrin is incorporated into endogenous postsynaptic protein complexes (Fig. 3F). In conclusion, these experiments suggest a role for NF166 in the control of gephyrin cluster size.
We further observed no impact of lentiviral shNF252-mediated knockdown of neurofascin on endogenous gephyrin clustering in hippocampal neurons (Fig. 3, D and E). The obvious difference in the in vivo experiments may be explained by the divergent expression pattern of neurofascin isoforms in vitro (see above) as well as incomplete maturation of cultured hippocampal neurons. Therefore, we examined the maturation state of GABAergic synapses at the AIS of hippocampal neurons. As shown in Fig. 3, I and J, neurofascin and the AIS marker protein phospho-IKBα (25) are coexpressed at the AIS. However, a considerable number of postsynaptic gephyrin clusters on phospho-IKBα-labeled AIS (Fig. 3J′) were devoid of opposed GAD65-positive terminals (see arrowheads in Fig. 3, J–J‴). Consequently, cultured neurons showed only partial elaboration of pre- and postsynaptic elements at the AIS, indicating incomplete maturation. By contrast, essentially all gephyrin clusters colocalize with GABAergic terminals at the AIS of adult brain in vivo (Fig. 1E).
NF166 Regulates Gephyrin Cluster Size in Hippocampal Neurons via FGFR1 Signaling
Neurofascin is a member of a class of cell adhesion molecules including NCAM and L1 that are thought to act via FGFR1 signaling (17, 26, 27). We therefore investigated a possible role of FGFR1 signaling in gephyrin clustering at the AIS after cotransfection of hippocampal neurons with neurofascin, EGFP-gephyrin, and a dominant negative mutant of FGFR1 (dnFGFR1). Overexpression of dnFGFR1 reduced gephyrin cluster size in the presence of neurofascin NF166 to the level of controls lacking NF166 (Fig. 4C). The same outcome was found for the application of the specific FGFR1 inhibitor SU5402. However, both SU5402 and dnFGFR1 did not impair EGFP-gephyrin cluster size in control neurons in the absence of NF166 overexpression, indicating that FGFR1 signaling is not involved in basal gephyrin clustering, but may contribute to the neurofascin-dependent organization of gephyrin clustering.
Neurofascin Expression Enhances Gephyrin Clustering in HeLa Cells
To study the function of neurofascin in a further independent model we made use of non-neuronal cells as a tool to study gephyrin clustering (4, 28, 29). HeLa cells were transiently transfected with expression vectors for neurofascin, EGFP-gephyrin, and the neuronal RhoGEF collybistin that is essential for translocating gephyrin to submembrane microaggregates (4, 29). We chose a constitutively active collybistin variant (CB2SH3−) because we wished to assess the impact of neurofascin on gephyrin clustering in the absence of neuroligin 2, which activates collybistin splice variants containing the src homology domain (4).
Expression of neurofascin isoform NF166 increased EGFP-gephyrin submembrane cluster size in the presence of collybistin compared with cells expressing other cell adhesion molecules such as NCAM, L1 or control transfected cells (Fig. 5, A–C). Quantitative immunofluorescence revealed a 70% increase in the average area of EGFP-gephyrin clusters compared with controls (Fig. 5C). Interestingly, the increase in cluster size is accompanied by a decrease in cluster number, suggesting fusion of gephyrin molecules into larger protein complexes (Fig. 5F). In addition, confocal analysis revealed that neurofascin is largely excluded from clustered EGFP-gephyrin in HeLa cells (Fig. 5B″). A NF166 deletion mutant lacking the intracellular domain of neurofascin did not increase gephyrin cluster size as observed in primary neurons. However, expression of NF186 or the neurofascin deletion mutant NF-CD lacking extracellular domains also induced gephyrin cluster size in a manner comparable to NF166 (Fig. 5C). Thus, the specificity for NF166 versus NF186 in the control of gephyrin clustering and the requirement of full-length neurofascin observed in primary neurons have been lost in the HeLa cell model.
As found in primary neurons, neurofascin-dependent gephyrin clustering in HeLa cells was abolished by coexpression of dn-FGFR1, but not of wild-type FGFR1 (Fig. 5D). This finding was further corroborated by the observation that both the specific FGFR inhibitor SU5402 and the inhibitor Ly94002 specific for the FGFR downstream component PI3K decrease neurofascin-dependent gephyrin clustering (Fig. 5E). In summary, these results imply that neurofascin-dependent gephyrin clustering may be controlled in HeLa cells by FGFR1 signaling principally as observed in primary neurons.
Neurofascin Modulates the Clustering of Inhibitory GABAA Receptors
We also assessed the possible impact of neurofascin on the clustering of α2β3γ2 GABAARs that reside on the AIS of hippocampal neurons (30). This was accomplished by expressing EGFP-tagged γ2 with untagged α2/β3 subunits in combination with collybistin and gephyrin in HeLa cells. As shown in Fig. 6A, gephyrin detected by immunocytochemistry perfectly colocalizes with γ2-EGFP, indicating that GABAARs were assembled correctly and associated with submembrane gephyrin. In the presence of neurofascin (Fig. 6B), colocalization of gephyrin with γ2-EGFP was retained. However, GABAAR clusters appeared to be fused into larger aggregates. Accordingly, quantification of the average area of individual γ2-EGFP clusters demonstrated that neurofascin expression results in increased average γ2-EGFP cluster size (Fig. 6C). By contrast, γ2-EGFP cluster areas remained unchanged after overexpression of NCAM.
DISCUSSION
This study demonstrates that neurofascin knockdown impairs both gephyrin and GABAAR clustering as well as the stability of GABAergic input at the AIS in vivo. Likewise, neurofascin appeared to be involved both in the regulation of the number and the size of gephyrin clusters. Moreover, gephyrin cluster size was also controlled by neurofascin in two distinct in vitro model systems, in hippocampal neurons and in HeLa cells, presumably dependent on FGFR1 signaling.
In the hippocampus, the AIS of dentate gyrus granular cells is targeted by axo-axonic terminals almost exclusively derived from chandelier neurons (6). The site of inhibitory input is thought to be strategic, because these terminals control the activity of principal neurons. Our results indicate that neurofascin may play an important role in the stabilization of axo-axonic input at the AIS of granular cells in vivo.
To get more insight into molecular mechanisms involved, our analysis relied on the use of two in vitro models including hippocampal neurons and a HeLa cell model. In a similar approach, non-neuronal cells such as HEK-293 cells were previously used to dissect mechanisms of gephyrin clustering (4, 28, 29). However, experimental limitations of the HeLa cell model need to be considered because tumor cells may make use of signaling pathways presumably different from those found in neurons. On the other hand, one of the key findings that FGFR1 signaling may contribute to neurofascin NF166-dependent gephyrin clustering was reproduced both in hippocampal neurons and in HeLa cells. The results also need to be cautiously interpreted because relevant neuronal factors may be missing in this model system. For instance, both NF166 and NF186 induced gephyrin clustering in HeLa cells, equally. This was not observed in cultured neurons where only NF166 was effective.
Neurofascin knockdown reduces clustering of gephyrin and GABAA receptors. The finding raises the question which of these pre- and postsynaptic components is primarily addressed by neurofascin. Gephyrin, a scaffolding component of GABAARs, is associated with gephyrin and collybistin (29, 31). Several reports suggest that basal assembly of this protein complex is independent of neurofascin expression (29, 31, 32). Therefore, neurofascin may be more implicated in functions of gephyrin cluster stabilization or size control, specifically at the AIS.
We also observed reduction of GAD65-positive presynaptic terminals after neurofascin knockdown in vivo. As a cell surface protein expressed in postsynaptic cells, neurofascin may trigger presynaptic stabilization via transsynaptic adhesion to presynaptic ligands very similar to e.g. neurexin-neuroligin or ephrinB-EphB interactions (33–36). Interference with neurofascin expression may therefore release synaptic contact. However, neurofascin is evenly distributed at the AIS of postsynaptic cells and does not display clustered expression at the subsynaptic membrane as shown for the other cell adhesion molecules, which argues against a specific role in transsynaptic adhesion. Alternatively, neurofascin may indirectly control presynaptic stabilization via stabilization of the GABAAR-gephyrin cluster complex. In case of neurofascin knockdown, disturbed expression and localization of GABAARs per se may be sufficient to destabilize presynaptic input (37). Hence, transsynaptic adhesion may not represent an absolute requirement for neurofascin-dependent presynaptic stabilization.
Considering mechanistic possibilities of neurofascin-dependent gephyrin clustering, neurofascin may be integrated into gephyrin-associated protein complexes at subsynaptic membranes. So far, we could not provide evidence for a direct interaction of neurofascin with gephyrin because neither yeast two-hybrid nor immunoprecipitation assays showed any direct or indirect interaction.5 In the HeLa cell model, neurofascin appeared to be excluded from submembrane gephyrin clusters. The exclusion of neurofascin from sites of submembrane gephyrin clusters may be explained by steric hindrance. Interaction of membrane-associated gephyrin with cytosolic interaction partners including microtubules may displace the cytosolic domain of neurofascin (38). Alternatively, the link between neurofascin and gephyrin clustering may rely on FGFR1 signaling which is required for gephyrin clustering both in hippocampal neurons and in HeLa cells. Neurofascin is able to interact with FGFR1 via intra- as well as extracellular domains, and neurofascin-dependent FGFR1 signaling is involved in the induction of neurite outgrowth upon homophilic interaction in embryonic neurons (17). Association with FGFR1 signaling and control of synaptic organization are properties shared with other cell adhesion molecules e.g. NCAM (17, 26, 27). NCAM regulates the formation or stabilization of excitatory synapses on dendrites (39). Altogether, the findings raise the interesting possibility that FGFR1 signaling is involved both in inhibitory and excitatory synapse stabilization via interaction with cell adhesion molecules.
Our results also suggest different roles of neurofascin isoforms in gephyrin clustering because NF186 did not increase gephyrin cluster size in contrast to NF166. NF186 is expressed predominantly in adult brain, suggesting a possible role for the stabilization of gephyrin clusters. Accordingly, NF186 was recently defined as a central element for the anchoring of AIS components (40). On the other hand, our experiments suggest an additional role for neurofascin in the dynamics of gephyrin clustering. The observation that NF166 modulated gephyrin cluster size at the AIS of hippocampal neurons is in line with this assumption. In a previous report, low density cultures of hippocampal neurons served as a model for the de novo formation of gephyrin clusters at the soma and the axon hillock (18). These immature neurons were devoid of completely differentiated AIS and expressed NF166, exclusively. Heterochronous expression of NF186 reduced the number of gephyrin punctae at the soma and therefore interfered with de novo gephyrin cluster formation. Presumably, NF186 competed for interaction partners of endogenous NF166 which were required for the formation of gephyrin clusters. By contrast, NF166 overexpression in the more mature neurons shown here modulated the size and not the number of preexisting gephyrin clusters at the AIS. In conclusion, different hippocampal model systems appear to reveal distinct neurofascin functions.
NF186 and NF166 represent two of a variety of neurofascin isoforms expressed in brain. Differences in the expression of extracellular domains account for selective interactions with extracellular ligands (19, 24, 41). Hence, the different functions of NF186 and NF166 may rely on selective recognition of extracellular ligand proteins. Different extracellular candidate interaction partners have been identified, including cell surface proteins axonin-1, F11/contactin, and NrCAM as well as with the component of the extracellular matrix tenascin-R (19, 42, 43). Of particular interest for an involvement in gephyrin clustering is NrCAM which is specifically coexpressed with neurofascin at the AIS of Purkinje neurons (44).
It was a surprising observation that NF166 decreased endogenous gephyrin cluster size whereas increased cluster size was measured in the presence of overexpressed EGFP-gephyrin. Control transfections as well as the finding that EGFP-gephyrin was incorporated into endogenous gephyrin clusters argue against overexpression artifacts as a possible reason. Furthermore, sensitivity of EGFP-gephyrin clustering to inhibition of FGFR1 signaling indicated further specificity for neurofascin-dependent mechanism. One explanation may be put forth by the dual properties of hippocampal neurons under study. These neurons displayed features of mature stabilized structures as exemplified by “adult” NF186 expression and completed organization of AIS components including expression of gephyrin clusters. However, coexpression of “embryonic” NF166 as well as the only partial elaboration of presynaptic terminals implied aspects of incomplete maturation. Gephyrin clusters located at the AIS of hippocampal neurons may require NF186 for stabilization. If neurons were overloaded with NF166, NF166 could compete with endogenous NF186 for binding to factors involved in gephyrin cluster stabilization. Consequently, endogenous gephyrin clusters may become destabilized. By contrast, simultaneous overexpression of EGFP-gephyrin might provide a pool of gephyrin amenable to NF166-mediated integration into preformed gephyrin clusters. In this case the destabilizing properties of NF166 are counteracted by increased gephyrin cluster assembly resulting in net increased gephyrin cluster size.
A picture of the organization of inhibitory synapses on principal neurons now becomes clearer. Neuroligin 2 is a major player to assemble dendritic and perisomatic inhibitory synapses (4, 45). Neurofascin represents a further cell surface molecule implicated in the organization of GABAergic synapses at the AIS. A function of neurofascin for synapse organization at dendrites or in the perisomatic compartment is less probable. Both the restricted expression of neurofascin at the AIS and the finding that neurofascin knockdown does not impair GABAergic innervation outside of the AIS argue against this possibility. Whether neuroligin 2 is also involved in gephyrin clustering at the AIS, remains elusive.
Supplementary Material
Acknowledgments
We thank Ursula Härle for technical assistance and Annyesha Mohanti for help constructing GABAA receptor expression plasmids, G. O'Sullivan for the EGFP-gephyrin, and Pavel Osten for the CamKII promoter constructs.
This work was supported in part by European Union Grant LSHM-CT-2005-512012 and Bundesministerium für Bildung und Forschung Grant 0315512 (to H. V.) and Medical Research Council Grants G0501258 and G0800498 (to K. H. and R. J. H.).
The on-line version of this article (available at http://www.jbc.org) contains supplemental text and a figure.
M. Kriebel, J. Metzger, S. Trinks, D. Chugh, R. J. Harvey, K. Harvey, and H. Volkmer, unpublished data.
- AIS
- axon initial segment
- CAM
- cell adhesion molecule
- CamKII
- Ca2+/calmodulin-dependent protein kinase II
- CB
- collybistin
- DIV
- days in vitro
- dnFGFR1
- dominant negative FGF receptor 1
- EGFP
- enhanced green fluorescent protein
- FGFR1
- fibroblast growth factor receptor 1
- FNIII
- fibronectin type III
- GABA
- γ-aminobutyric acid
- GABAAR
- GABA type A receptor
- GAD65
- glutamate decarboxylase
- GAT-1
- GABA transporter 1
- NCAM
- neural cell adhesion molecule
- NF
- neurofascin
- VGSC
- voltage-gated sodium channel.
REFERENCES
- 1. Gerrow K., El-Husseini A. (2006) Front. Biosci. 11, 2400–2419 [DOI] [PubMed] [Google Scholar]
- 2. Chih B., Engelman H., Scheiffele P. (2005) Science 307, 1324–1328 [DOI] [PubMed] [Google Scholar]
- 3. Graf E. R., Zhang X., Jin S. X., Linhoff M. W., Craig A. M. (2004) Cell 119, 1013–1026 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Poulopoulos A., Aramuni G., Meyer G., Soykan T., Hoon M., Papadopoulos T., Zhang M., Paarmann I., Fuchs C., Harvey K., Jedlicka P., Schwarzacher S. W., Betz H., Harvey R. J., Brose N., Zhang W., Varoqueaux F. (2009) Neuron 63, 628–642 [DOI] [PubMed] [Google Scholar]
- 5. Somogyi P., Smith A. D., Nunzi M. G., Gorio A., Takagi H., Wu J. Y. (1983) J. Neurosci. 3, 1450–1468 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Howard A., Tamas G., Soltesz I. (2005) Trends Neurosci. 28, 310–316 [DOI] [PubMed] [Google Scholar]
- 7. Woodruff A. R., Anderson S. A., Yuste R. (2010) Front. Neurosci. 4, 201 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Lewis D. A. (2011) Dev. Neurobiol. 71, 118–127 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ogawa Y., Rasband M. N. (2008) Curr. Opin. Neurobiol. 18, 307–313 [DOI] [PubMed] [Google Scholar]
- 10. Kordeli E., Lambert S., Bennett V. (1995) J. Biol. Chem. 270, 2352–2359 [DOI] [PubMed] [Google Scholar]
- 11. Berghs S., Aggujaro D., Dirkx R., Jr., Maksimova E., Stabach P., Hermel J. M., Zhang J. P., Philbrick W., Slepnev V., Ort T., Solimena M. (2000) J. Cell Biol. 151, 985–1002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Jenkins S. M., Bennett V. (2001) J. Cell Biol. 155, 739–746 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Hassel B., Rathjen F. G., Volkmer H. (1997) J. Biol. Chem. 272, 28742–28749 [DOI] [PubMed] [Google Scholar]
- 14. Hedstrom K. L., Xu X., Ogawa Y., Frischknecht R., Seidenbecher C. I., Shrager P., Rasband M. N. (2007) J. Cell Biol. 178, 875–886 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ratcliffe C. F., Westenbroek R. E., Curtis R., Catterall W. A. (2001) J. Cell Biol. 154, 427–434 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Sherman D. L., Tait S., Melrose S., Johnson R., Zonta B., Court F. A., Macklin W. B., Meek S., Smith A. J., Cottrell D. F., Brophy P. J. (2005) Neuron 48, 737–742 [DOI] [PubMed] [Google Scholar]
- 17. Kirschbaum K., Kriebel M., Kranz E. U., Pötz O., Volkmer H. (2009) J. Biol. Chem. 284, 28533–28542 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Burkarth N., Kriebel M., Kranz E. U., Volkmer H. (2007) Mol. Cell. Neurosci. 36, 59–70 [DOI] [PubMed] [Google Scholar]
- 19. Pruss T., Kranz E. U., Niere M., Volkmer H. (2006) Mol. Cell. Neurosci. 31, 354–365 [DOI] [PubMed] [Google Scholar]
- 20. Freund T. F., Buzsáki G. (1996) Hippocampus 6, 347–470 [DOI] [PubMed] [Google Scholar]
- 21. Hardwick C., French S. J., Southam E., Totterdell S. (2005) Brain Res. 1031, 238–244 [DOI] [PubMed] [Google Scholar]
- 22. McEwen D. P., Isom L. L. (2004) J. Biol. Chem. 279, 52744–52752 [DOI] [PubMed] [Google Scholar]
- 23. Dzhashiashvili Y., Zhang Y., Galinska J., Lam I., Grumet M., Salzer J. L. (2007) J. Cell Biol. 177, 857–870 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Koticha D., Babiarz J., Kane-Goldsmith N., Jacob J., Raju K., Grumet M. (2005) Mol. Cell. Neurosci. 30, 137–148 [DOI] [PubMed] [Google Scholar]
- 25. Schultz C., König H. G., Del Turco D., Politi C., Eckert G. P., Ghebremedhin E., Prehn J. H., Kögel D., Deller T. (2006) Mol. Cell. Neurosci. 33, 68–80 [DOI] [PubMed] [Google Scholar]
- 26. Ditlevsen D. K., Povlsen G. K., Berezin V., Bock E. (2008) J. Neurosci. Res. 86, 727–743 [DOI] [PubMed] [Google Scholar]
- 27. Maness P. F., Schachner M. (2007) Nat. Neurosci. 10, 19–26 [DOI] [PubMed] [Google Scholar]
- 28. Harvey K., Duguid I. C., Alldred M. J., Beatty S. E., Ward H., Keep N. H., Lingenfelter S. E., Pearce B. R., Lundgren J., Owen M. J., Smart T. G., Lüscher B., Rees M. I., Harvey R. J. (2004) J. Neurosci. 24, 5816–5826 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Saiepour L., Fuchs C., Patrizi A., Sassoè-Pognetto M., Harvey R. J., Harvey K. (2010) J. Biol. Chem. 285, 29623–29631 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Nusser Z., Sieghart W., Benke D., Fritschy J. M., Somogyi P. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 11939–11944 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Tretter V., Jacob T. C., Mukherjee J., Fritschy J. M., Pangalos M. N., Moss S. J. (2008) J. Neurosci. 28, 1356–1365 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Jacob T. C., Moss S. J., Jurd R. (2008) Nat. Rev. Neurosci. 9, 331–343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Song J. Y., Ichtchenko K., Südhof T. C., Brose N. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 1100–1105 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Dalva M. B., Takasu M. A., Lin M. Z., Shamah S. M., Hu L., Gale N. W., Greenberg M. E. (2000) Cell 103, 945–956 [DOI] [PubMed] [Google Scholar]
- 35. Varoqueaux F., Jamain S., Brose N. (2004) Eur. J. Cell Biol. 83, 449–456 [DOI] [PubMed] [Google Scholar]
- 36. Craig A. M., Graf E. R., Linhoff M. W. (2006) Trends Neurosci. 29, 8–20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Li R. W., Yu W., Christie S., Miralles C. P., Bai J., Loturco J. J., De Blas A. L. (2005) J. Neurochem. 95, 756–770 [DOI] [PubMed] [Google Scholar]
- 38. Fritschy J. M., Harvey R. J., Schwarz G. (2008) Trends Neurosci. 31, 257–264 [DOI] [PubMed] [Google Scholar]
- 39. Cambon K., Hansen S. M., Venero C., Herrero A. I., Skibo G., Berezin V., Bock E., Sandi C. (2004) J. Neurosci. 24, 4197–4204 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Zonta B., Desmazieres A., Rinaldi A., Tait S., Sherman D. L., Nolan M. F., Brophy P. J. (2011) Neuron 69, 945–956 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Basak S., Raju K., Babiarz J., Kane-Goldsmith N., Koticha D., Grumet M. (2007) Dev. Biol. 311, 408–422 [DOI] [PubMed] [Google Scholar]
- 42. Volkmer H., Leuschner R., Zacharias U., Rathjen F. G. (1996) J. Cell Biol. 135, 1059–1069 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Volkmer H., Zacharias U., Nörenberg U., Rathjen F. G. (1998) J. Cell Biol. 142, 1083–1093 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Davis J. Q., Lambert S., Bennett V. (1996) J. Cell Biol. 135, 1355–1367 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Chubykin A. A., Atasoy D., Etherton M. R., Brose N., Kavalali E. T., Gibson J. R., Südhof T. C. (2007) Neuron 54, 919–931 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.